# Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis

> **NCT07055724** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Nanjing IASO Biotechnology Co., Ltd.** · enrollment: 17 (estimated)

## Conditions studied

- AL Amyloidosis

## Interventions

- **BIOLOGICAL:** Eque-cel CAR-T Therapy

## Key facts

- **NCT ID:** NCT07055724
- **Lead sponsor:** Nanjing IASO Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 17 (ESTIMATED)
- **Last updated:** 2025-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07055724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07055724, "Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07055724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*